“Continuous Weekly Adalimumab Is the Optimal Long-Term Strategy for Patients With Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1):s129. https://doi.org/10.25251/skin.1.supp.128.